The stock of Gain Therapeutics Inc (GANX) has gone up by 12.96% for the week, with a 36.31% rise in the past month and a 23.23% rise in the past quarter. The volatility ratio for the week is 15.38%, and the volatility levels for the past 30 days are 10.94% for GANX. The simple moving average for the past 20 days is 30.03% for GANX’s stock, with a 22.23% simple moving average for the past 200 days.
Is It Worth Investing in Gain Therapeutics Inc (NASDAQ: GANX) Right Now?
The 36-month beta value for GANX is at 0.14. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for GANX is 25.22M, and currently, shorts hold a 1.33% of that float. The average trading volume for GANX on January 10, 2025 was 298.72K shares.
GANX) stock’s latest price update
Gain Therapeutics Inc (NASDAQ: GANX)’s stock price has gone rise by 7.49 in comparison to its previous close of 2.27, however, the company has experienced a 12.96% increase in its stock price over the last five trading days. zacks.com reported 2025-01-09 that GANX, FHB and TRV made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 9, 2024.
Analysts’ Opinion of GANX
Many brokerage firms have already submitted their reports for GANX stocks, with ROTH MKM repeating the rating for GANX by listing it as a “Buy.” The predicted price for GANX in the upcoming period, according to ROTH MKM is $7 based on the research report published on December 06, 2024 of the previous year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see GANX reach a price target of $8. The rating they have provided for GANX stocks is “Outperform” according to the report published on August 14th, 2024.
Oppenheimer gave a rating of “Outperform” to GANX, setting the target price at $30 in the report published on April 12th of the previous year.
GANX Trading at 26.18% from the 50-Day Moving Average
After a stumble in the market that brought GANX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.22% of loss for the given period.
Volatility was left at 10.94%, however, over the last 30 days, the volatility rate increased by 15.38%, as shares surge +33.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.92% lower at present.
During the last 5 trading sessions, GANX rose by +12.96%, which changed the moving average for the period of 200-days by -39.90% in comparison to the 20-day moving average, which settled at $1.88. In addition, Gain Therapeutics Inc saw 12.96% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GANX starting from Mack Gene, who purchase 14,400 shares at the price of $1.01 back on Aug 09 ’24. After this action, Mack Gene now owns 14,400 shares of Gain Therapeutics Inc, valued at $14,544 using the latest closing price.
Islam Khalid, the Executive Chairman of Gain Therapeutics Inc, purchase 50,000 shares at $1.00 during a trade that took place back on Aug 09 ’24, which means that Islam Khalid is holding 50,000 shares at $49,940 based on the most recent closing price.
Stock Fundamentals for GANX
Current profitability levels for the company are sitting at:
- -330.66 for the present operating margin
- 0.0 for the gross margin
The net margin for Gain Therapeutics Inc stands at -329.74. The total capital return value is set at -2.19. Equity return is now at value -263.14, with -150.14 for asset returns.
Based on Gain Therapeutics Inc (GANX), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -42.64.
Currently, EBITDA for the company is -22.17 million with net debt to EBITDA at 0.53. When we switch over and look at the enterprise to sales, we see a ratio of 824.71. The receivables turnover for the company is 0.17for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.99.
Conclusion
In conclusion, Gain Therapeutics Inc (GANX) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
